BCL11B Antibody
-
货号:CSB-PA880159HA01HU
-
规格:¥440
-
促销:
-
图片:
-
其他:
产品详情
-
产品名称:Rabbit anti-Homo sapiens (Human) BCL11B Polyclonal antibody
-
Uniprot No.:Q9C0K0
-
基因名:BCL11B
-
别名:ATL1 alpha antibody; ATL1 antibody; ATL1 beta antibody; ATL1 gamma antibody; ATL1-delta antibody; B cell CLL/lymphoma 11B/T cell receptor delta constant region fusion protein antibody; B cell lymphoma/leukemia 11B antibody; B-cell CLL/lymphoma 11B (zinc finger protein) antibody; B-cell CLL/lymphoma 11B antibody; B-cell lymphoma/leukemia 11B antibody; BC11B_HUMAN antibody; BCL-11B antibody; Bcl11b antibody; BCL11B/TRDC fusion antibody; COUP TF interacting protein 2 antibody; COUP-TF interacting protein 2 antibody; COUP-TF-interacting protein 2 antibody; Ctip 2 antibody; CTIP-2 antibody; CTIP2 antibody; hRIT1 alpha antibody; hRit1 antibody; Radiation induced tumor suppressor gene 1 antibody; Radiation induced tumor suppressor gene 1 protein antibody; Radiation-induced tumor suppressor gene 1 protein antibody; Rit 1 antibody; Rit1 antibody; zinc finger protein hRit1 alpha antibody; ZNF856B antibody
-
宿主:Rabbit
-
反应种属:Human
-
免疫原:Recombinant Human B-cell lymphoma/leukemia 11B protein (500-550AA)
-
免疫原种属:Homo sapiens (Human)
-
标记方式:Non-conjugated
本页面中的产品,BCL11B Antibody (CSB-PA880159HA01HU),的标记方式是Non-conjugated。对于BCL11B Antibody,我们还提供其他标记。见下表:
-
克隆类型:Polyclonal
-
抗体亚型:IgG
-
纯化方式:>95%, Protein G purified
-
浓度:It differs from different batches. Please contact us to confirm it.
-
保存缓冲液:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
产品提供形式:Liquid
-
应用范围:ELISA, IHC
-
推荐稀释比:
Application Recommended Dilution IHC 1:200-1:500 -
Protocols:
-
储存条件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
货期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
相关产品
靶点详情
-
功能:Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes. Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element. May also function in the P53-signaling pathway.
-
基因功能参考文献:
- These results suggest that the upregulation of miR-650 contributes to the development of acute renal allograft rejection by suppression of BCL11B, which leads to apoptosis and inflammatory responses. Thus, miR-650 and BCL11B may represent potential therapeutic targets for the prevention of acute renal allograft rejection. PMID: 29039465
- In this present work, the s identify and characterize a transcription factor i.e. HIC1, which physically interacts with both Bcl11b/CTIP2 and HMGA1 to co-regulate specific subsets of cellular genes and the HIV-1 tat gene. PMID: 27725726
- Decreased transcript and increased promoter methylation levels of BCL11B gene were identified in ankylosing spondylitis patients. PMID: 28794504
- this is the first study to show that the inhibition of Bcl11b suppresses glioma cell growth by regulating the expression of the cell cycle regulator p21 and stemness-associated genes (Sox-2/Bmi-1). PMID: 26096706
- studies show BCL11B is a key regulator of the initial stages of human T-cell differentiation and delineate the BCL11B transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL PMID: 28232744
- BCL11B showed increased but varied expression in advanced tumor stage. Analysis of four patients receiving SAHA treatment suggested a positive correlation between BCL11B expression and favorable response to SAHA treatment. In conclusion, BCL11B may serve as a therapeutic target and a useful marker for improving HDACi efficacy in advanced CTCL. PMID: 28288848
- Human T-cell leukemia virus type 1 (HTLV-1) Tax directly binds to BCL11B. Tax enhances BCL11B degradation through proteasome pathway. Loss of BCL11B enhances cell growth in HTLV-1-infected cells. PMID: 28669733
- Findings identify BCL11B Ser2 phosphorylation as a new mandatory step in the interconnected posttranslational modifications converting BCL11B from a transcriptional repressor to an activator. PMID: 27161321
- BCL11B introduction in human cell lines downregulated transcription of beta-catenin target genes, whereas Bcl11b attenuation in Lgr5(+) crypt base columnar cells increased expression of beta-catenin targets including c-Myc and cyclin D1. PMID: 25827435
- Tax is responsible for suppressing BCL11B protein expression in HTLV-1-infected T-cells; Tax-mediated repression of BCL11B is another mechanism that Tax uses to promote oncogenesis of HTLV-1-infected T-cells. PMID: 25613934
- low BCL11b expression was associated with poor prognosis; particularly in the standard risk group of thymic T-cell acute lymphoblastic leukemia PMID: 25023966
- Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations. PMID: 24441149
- a comprehensive review of the roles of Bcl11b in progenitors, effector T cells, regulatory T cells, and invariant NKT cells, as well as its impact on immune diseases. PMID: 25128552
- overexpressed in mycosis fungoides lesions PMID: 23682716
- CTIP2 controls P-TEFb function in physiological and pathological conditions. PMID: 23852730
- BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. PMID: 23527175
- a reduction in the level of the BCL11B protein is a key event in the multistep progression of ATLL leukemogenesis PMID: 23383087
- BLC11B is an oncogene in T-ALL pathogenesis. PMID: 23040356
- BCL11B gene silencing alone does not affect hematopoietic stem/progenitor cell proliferation and differentiation in vitro. PMID: 23168072
- REVIEW: describes phenotypes given by loss of Bcl11b and roles of Bcl11b in cell proliferation, differentiation and apoptosis, taking tissue development and lymphomagenesis into consideration PMID: 22450536
- Bcl11b phospho-deSUMO switch was identified, the basis of which was phosphorylation-dependent recruitment of the SUMO hydrolase SENP1 to phospho-Bcl11b, coupled to hydrolysis of SUMO-Bcl11b PMID: 22700985
- Common genetic variation in a locus in the BCL11B gene desert that is thought to harbor 1 or more gene enhancers is associated with higher CFPWV and increased risk for cardiovascular disease. PMID: 22068335
- BCL11B directly interacts with P2 promoter region of HDM2 and inhibits HDM2 promoter activity in a p53-dependent manner. PMID: 22245141
- BCL11B is a haploinsufficient tumor suppressor that collaborates with all major T-ALL oncogenic lesions in human thymocyte transformation. PMID: 21878675
- This study proposed that the expression of CTIP2 in the anterior neocortex may mark the early location of the human motor cortex, including its corticospinal projection neurons, allowing further study of their early differentiation. PMID: 21060114
- BCL11B might play a role in anti-apoptosis in T-ALL cells through up-regulation of its downstream genes BCL2L1 and CREBBP. PMID: 21080944
- Increased expression of bcl11b leads to chemoresistance and G1 arrest. PMID: 20824091
- CTIP2 expression could be linked to disease progression and/or maintenance in human atopic dermatitis and allergic contact dermatitis PMID: 19366371
- CTIP2 mediates transcriptional repression with SIRT1 in mammmalian cells PMID: 12930829
- To our knowledge, this is the first report implicating BCL11B in hematological malignancies. PMID: 15104287
- BCL11B is involved in hematological neoplasms of T-cells but not acute myeloid leukemia. PMID: 15325104
- BCL11B appears to play a key role in T-cell differentiation, BCL11B disruption and disturbed expression may contribute to the development of T-cell malignancies in man. PMID: 15668700
- transcriptional repression fuction is mediated by NuRD complex PMID: 16091750
- CTIP2 recruits histone deacetylase (HDAC)1 and HDAC2 to promote local histone H3 deacetylation at the HIV-1 promoter region. PMID: 17245431
- Data document homeobox gene dysregulation by a novel regulatory region at 3'-BCL11B responsive to histone deacetylase inhibition and highlight a novel class of potential therapeutic target amid noncoding DNA. PMID: 17308084
- Bcl11b has a role in response to DNA replication stress and damages PMID: 17369851
- We propose that sequestration and/or decreased expression of Bcl11b in HD is responsible, at least in part, for the dysregulation of striatal gene expression observed in HD and may contribute to the specificity of pathology observed in this disease. PMID: 18595722
- The s provide evidence that the transcription factor BCL11B represses expression from the HIV-1 long terminal repeat (LTR) in T lymphocytes through direct association with the HIV-1 long terminal repeat. PMID: 18768194
- A statistically significant increase in the expression of CTIP2 was detected in poorly differentiated samples of head and neck tumors. PMID: 19399189
- CTIP2 is a constitutive p21 gene suppressor that cooperates with SUV39H1 and histone methylation to silence the p21 gene transcription. PMID: 19581932
显示更多
收起更多
-
相关疾病:Immunodeficiency 49 (IMD49)
-
亚细胞定位:Nucleus.
-
组织特异性:Highly expressed in brain and in malignant T-cell lines derived from patients with adult T-cell leukemia/lymphoma.
-
数据库链接:
HGNC: 13222
OMIM: 606558
KEGG: hsa:64919
STRING: 9606.ENSP00000349723
UniGene: Hs.709690
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-